Edwards Lifesciences Corp
EWNYSE · SIC 3842
$85.73
↓ -2.4%Jul 17 close · end-of-day
Price
1Y↑ +12.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$49.8B
Enterprise Value
$46.7B
P/E
45.6
P/S
7.9
P/B
4.8
EV/EBITDA
31.0
PEG
—
FCF Yield
2.2%
Dividend Yield
—
Revenue (TTM)
$6.3B
Net Income (TTM)
$1.1B
Free Cash Flow (TTM)
$1.1B
Gross Margin
77.9%
Operating Margin
21.4%
Net Margin
17.4%
ROE
10.6%
ROIC
15.3%
Debt / Equity
0.1
Net Cash
$3.1B
Return 1Y
+12.5%
Company profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, critical care and surgical monitoring. It offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name. The company distributes its products through a direct sales force and independent distributors.
- CEO
- Michael A. Mussallem
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 17,300
- Headquarters
- California
- Website
- edwards.com
Management & directors
- Bruls AnnetteCVP, EMEACLA
- Lippis Daniel J.CVP, JAPAC
- Mistras TheodoraCVP, Chief Financial Officer
- Zovighian Bernard JCEO
- Dahl Andrew M.SVP, Corporate Controller
- Bobo Donald E JrCVP,Strategy/Corp Development
- Chopra DaveenCVP, TMTT & Surgical
- Markowitz WayneCVP, JAPAC
- Ullem Scott B.CVP, Chief Financial Officer
- Wood Larry LGlobal President TAVR & Surg
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-23
EW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.6B↑ +16.7%
Diluted EPS$0.66↑ +8.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.4B | $5.2B | $4.5B | $5.0B | $5.4B | $6.1B |
| Gross profit | $3.3B | $4.0B | $3.7B | $4.0B | $4.3B | $4.7B |
| Operating income | $897.6M | $1.7B | $1.5B | $1.3B | $1.4B | $1.3B |
| Net income | — | $1.5B | $1.5B | $1.4B | $4.2B | $1.1B |
| Diluted EPS | $1.30 | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 |
| Operating cash flow | $1.1B | $1.7B | $1.2B | $895.8M | $542.3M | $1.6B |
| Free cash flow | $647.3M | $1.4B | $973.6M | $642.8M | $289.9M | $1.3B |
| Gross margin | 75.4% | 76.1% | 83.8% | 80.5% | 79.5% | 78.0% |
| Operating margin | 20.5% | 32.3% | 33.6% | 26.1% | 25.3% | 20.8% |
| Net margin | — | 28.7% | 34.1% | 28.0% | 76.7% | 17.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.4B | $1.4B | $1.4B | $1.5B | $1.6B | $1.6B | $1.6B |
| Gross profit | $1.1B | $1.1B | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B | $1.3B |
| Operating income | $366.5M | $350.6M | $312.6M | $394.8M | $411.2M | $307.1M | $151.1M | $477.6M |
| Net income | $366.3M | $3.1B | $385.6M | $358.0M | $333.2M | $291.1M | $91.2M | $380.7M |
| Diluted EPS | $0.61 | $5.13 | $0.65 | $0.61 | $0.56 | $0.50 | $0.16 | $0.66 |
| Operating cash flow | $371.5M | $351.8M | -$127.5M | $280.4M | $290.2M | $573.7M | $450.9M | $43.8M |
| Free cash flow | $286.1M | $299.9M | -$177.3M | $224.4M | $240.9M | $516.2M | $353.5M | -$21.1M |
| Gross margin | 79.9% | 80.6% | 78.9% | 78.7% | 77.5% | 77.8% | 78.1% | 78.0% |
| Operating margin | 26.8% | 25.9% | 22.6% | 27.9% | 26.8% | 19.8% | 9.6% | 29.0% |
| Net margin | 26.7% | 226.7% | 27.8% | 25.3% | 21.7% | 18.7% | 5.8% | 23.1% |
Company news
Jul 16, 2026
Jul 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-11 | Bruls Annette· CVP, EMEACLA | Tax withholding | 109 | $92.21 | $10,050.89 | filing |
| 2026-07-10 | Lippis Daniel J.· CVP, TAVR | Sale | 619 | $91.70 | $56,762.30 | filing |
| 2026-07-10 | Lippis Daniel J.· CVP, TAVR | Option exercise | 619 | $72.68 | $44,988.92 | filing |
| 2026-07-09 | Mistras Theodora· CVP, Chief Financial Officer | Award | 87,595 | $0.00 | $0.00 | filing |
| 2026-07-09 | Mistras Theodora· CVP, Chief Financial Officer | Award | 12,325 | $0.00 | $0.00 | filing |
| 2026-07-07 | Lippis Daniel J.· CVP, TAVR | Tax withholding | 377 | $95.18 | $35,882.86 | filing |
| 2026-06-30 | Lippis Daniel J.· CVP, TAVR | Sale | 619 | $91.40 | $56,576.72 | filing |
| 2026-06-30 | Lippis Daniel J.· CVP, TAVR | Option exercise | 619 | $72.68 | $44,988.92 | filing |
| 2026-06-17 | Zovighian Bernard J· CEO | Sale | 523 | $87.92 | $45,982.16 | filing |
| 2026-05-29 | Dahl Andrew M.· SVP, Corporate Controller | Sale | 568 | $86.08 | $48,852.69 | filing |
| 2026-05-27 | BOBO DONALD E JR· CVP,Strategy/Corp Development | Sale | 23,145 | $86.42 | $2.0M | filing |
| 2026-05-22 | Chopra Daveen· CVP, TMTT & Surgical | Sale | 1,500 | $84.60 | $126,905.25 | filing |
| 2026-05-18 | Lippis Daniel J.· CVP, TAVR | Sale | 620 | $81.14 | $50,306.80 | filing |
| 2026-05-18 | Lippis Daniel J.· CVP, TAVR | Option exercise | 620 | $72.68 | $45,061.60 | filing |
| 2026-05-15 | BOBO DONALD E JR· CVP,Strategy/Corp Development | Sale | 9,968 | $82.07 | $818,105.66 | filing |
| 2026-05-15 | BOBO DONALD E JR· CVP,Strategy/Corp Development | Sale | 8,000 | $81.82 | $654,572.80 | filing |
| 2026-05-12 | Zovighian Bernard J· CEO | Sale | 35,506 | $77.92 | $2.8M | filing |
| 2026-05-12 | Zovighian Bernard J· CEO | Sale | 845 | $78.40 | $66,250.28 | filing |
| 2026-05-12 | Zovighian Bernard J· CEO | Gift | 26,640 | $0.00 | $0.00 | filing |
| 2026-05-11 | Zovighian Bernard J· CEO | Tax withholding | 26,198 | $79.96 | $2.1M | filing |
| 2026-05-11 | Ullem Scott B.· CVP, Chief Financial Officer | Tax withholding | 11,004 | $79.96 | $879,879.84 | filing |
| 2026-05-11 | Chopra Daveen· CVP, TMTT & Surgical | Tax withholding | 7,538 | $79.96 | $602,738.48 | filing |
| 2026-05-11 | BOBO DONALD E JR· CVP,Strategy/Corp Development | Tax withholding | 7,469 | $79.96 | $597,221.24 | filing |
| 2026-05-11 | Markowitz Wayne· CVP, JAPAC | Sale | 593 | $79.73 | $47,279.89 | filing |
| 2026-05-11 | Lippis Daniel J.· CVP, TAVR | Tax withholding | 362 | $79.96 | $28,945.52 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.